Two Trials. One Day. Massive Numbers.

Eli Lilly released Phase 3 data on retatrutide on March 19, 2026 — and the results dominated headlines.

Two separate late-stage trials reported the same day. One in obesity patients. One in Type 2 diabetes patients. Both cleared their primary goals, according to CNBC and BioPharma Dive.

Retatrutide is a weekly injection, different from orforglipron (Foundayo), the pill covered previously. It works through a different mechanism.

What the Obesity Numbers Actually Mean

The highest dose of retatrutide helped patients lose 28.3% of their body weight — averaging 70.3 pounds — over 80 weeks, according to CNBC. The placebo group lost 2.2%.

Roughly 45% of the 2,500 trial participants achieved 30% or more weight loss at the highest dose. That level of loss has previously only been associated with bariatric surgery, according to Dan Skovronsky, Lilly's chief scientific and product officer. "We haven't seen that level of weight loss before with these kinds of medicines," Skovronsky told CNBC.

Around 65% of patients on the highest dose dropped their BMI below 30 — out of the obesity classification entirely — at 80 weeks.

For patients with a BMI of 35 or above who continued into a study extension, average weight loss hit 30.3% over 104 weeks.

The Diabetes Trial Numbers

Retatrutide also cleared its first late-stage diabetes trial. The drug lowered hemoglobin A1c by an average of 1.7% to 2% across doses over 40 weeks in Type 2 diabetes patients who started with A1c levels between 7% and 9.5%, according to CNBC and BioPharma Dive.

The two highest doses cut blood sugar by 1.9 percentage points from a baseline average of 7.9%, per BioPharma Dive. The placebo group dropped 0.8 points.

The highest dose helped diabetes patients lose an average of 16.8% of their body weight — or 36.6 pounds — at 40 weeks. Discontinuation rates due to side effects were up to 5%, which Ken Custer, president of Lilly Cardiometabolic Health, described as positive in a CNBC interview.

How This Drug Works Differently

Retatrutide is a triple-acting drug, targeting three gut hormones simultaneously — GLP-1, GIP, and glucagon receptors. Existing approved drugs like Zepbound (tirzepatide) hit two. This triple mechanism is expected to drive higher efficacy.

For context, Zepbound — currently one of the top-selling weight-loss pharmaceuticals in the world according to BioPharma Dive — produces around 20-22% weight loss. Retatrutide is clearing 28% at its highest dose. That's a significant increase.

Evercore ISI analyst Umer Raffat wrote in December 2025 that an earlier retatrutide trial put the entire obesity drug field on alert. The new obesity and diabetes results reinforce that assessment.

Side Effects Are Real — Don't Gloss Over Them

The drug showed higher rates of gastrointestinal side effects — nausea and diarrhea — particularly at the highest dose, according to CNBC. Some analysts have noted this correlates directly with the speed and intensity of weight loss the drug drives.

A lower dose in the obesity trial had fewer discontinuations due to side effects, which may become a real consideration when the FDA eventually reviews dose approval.

These aren't minor footnotes. At 28% weight loss, the body is undergoing rapid change. Patients and doctors will need to weigh those tradeoffs.

What Mainstream Coverage Is Getting Wrong

Most of the business press is framing this purely as a stock story — LLY share price, competitive advantage against Novo Nordisk, Wall Street analyst expectations. That's accurate as far as it goes, but incomplete.

Lilly has NOT yet filed for FDA approval of retatrutide for obesity or diabetes. These are trial results, not an approved drug. The company expects seven more Phase 3 trial readouts by end of 2026, according to CNBC.

There's also a cost question that few outlets are addressing. Zepbound currently runs over $500/month out of pocket for many Americans. Retatrutide, if approved, will likely be priced even higher given its efficacy profile. The $149/month pill orforglipron (Foundayo) looks more accessible for most patients — but it's less powerful. These are different tools with different tradeoffs.

What Comes Next

Lilly expects results from three more large obesity trials around mid-2026, per BioPharma Dive. Those are designed to maximize weight-loss outcomes — meaning the 28.3% number may not be the final ceiling.

The company hasn't filed for approval yet. FDA review takes time. Retatrutide is unlikely to reach pharmacy shelves in 2026.

The direction is clear: obesity treatment is shifting in real time, and Lilly is currently leading that transformation. Novo Nordisk, which makes Ozempic and Wegovy, faces serious competition.

The Bottom Line

Forty-five percent of patients losing 30% or more of their body weight. Numbers previously reserved for surgical intervention. A diabetes trial cleared the same day.

If these results hold through remaining trials and FDA review, retatrutide will be a category shift. The real question Americans should be asking isn't whether the science works. It's whether they'll be able to afford it.